Drug Trial Radar · NCT02735707
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20,000
Planned (sponsor's estimate)
Start
Apr 11, 2016
Primary completion
Jun 2028
Study completion Feb 2029
Sponsor
- Lead sponsor
- UMC UtrechtAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Australian and New Zealand Intensive Care Research Centre; Medical Research Institute of New Zealand; Unity Health; Berry Consultants; Global Coalition for Adaptive Research; University of Pittsburgh Medical Center; Intensive Care National Audit & Research Centre; St. Marianna University School of Medicine; Nat Intensive Care Surveillance - MORU; National University Hospital, Singapore; Clínica Universidad de La Sabana; Universidad de la Sabana
- First posted
- Apr 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 28 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised patients admitted to intensive care with respiratory tract infections. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
Conditions
- Respiratory Tract Diseases
- Influenza (Pandemic)
- Influenza
- Community Acquired Pneumonia
- Community Acquired Pneumonia (CAP)
- Community Acquired Pneumonia, Severe
- COVID-19
- Respiratory Tract Infection Acute
- Respiratory Tract Infections (RTI)
- SARS CoV 2 Infection
Interventions
Ceftriaxone + MacrolideDrug
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Moxifloxacin or LevofloxacinDrug
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Piperacillin-tazobactam + MacrolideDrug
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Ceftaroline + MacrolideDrug
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. Note: this intervention is now closed.
Amoxicillin-clavulanate + MacrolideDrug
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Standard course macrolideDrug
Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5. The dosing of and route of administration is not protocolised, the following guidance is provided: * Initial IV administration of a macrolide is strongly preferred * The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted. * The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Extended course macrolideDrug
Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first). The dosing of and route of administration is not protocolised, the following guidance is provided: * Initial IV administration of a macrolide is strongly preferred * The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted. * The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
No systemic corticosteroidOther
Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
Fixed-duration HydrocortisoneDrug
50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days. Note: this intervention is now closed.
Shock-dependent hydrocortisoneDrug
50mg IV hydrocortisone every 6 hours while the patient is in septic shock
Fixed-duration higher dose HydrocortisoneDrug
100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days. Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed.
No antiviral agent for influenzaOther
No antiviral agent intended to be active against influenza infection is to be administered
Five-days oseltamivirDrug
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
Ten-days oseltamivirDrug
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
No antiviral agent for COVID-19Other
No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
Lopinavir / RitonavirDrug
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Note: this intervention is now closed.
HydroxychloroquineDrug
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed.
Hydroxychloroquine + lopinavir/ritonavirDrug
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed.
IvermectinDrug
Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day. Note: this intervention is now closed.
No immune modulation for COVID-19Other
No immune modulating agent intended to be active against COVID-19 is to be administered. Note: this intervention is now closed.
Interferon beta-1aDrug
IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first. Note: this intervention is now closed.
AnakinraDrug
A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours. In patients with renal impairment, anakinra will be administered on alternate days. Note: this intervention is now closed.
TocilizumabDrug
Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period. Note: this intervention is now closed.
SarilumabDrug
Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period. Note: this intervention is now closed.
Local standard venous thromboprophylaxisDrug
Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
Therapeutic dose anticoagulationDrug
Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician. Note: this intervention is now closed.
Conventional low dose thromboprophylaxisDrug
Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Intermediate dose thromboprophylaxisDrug
Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Continuation of therapeutic dose anticoagulationDrug
Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
No immunoglobulinOther
No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.
Convalescent plasmaBiological
Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.
Delayed administration of convalescent plasmaBiological
Note: this intervention is now closed.
No vitamin COther
No high dose intravenous vitamin C is to be administered Note: this intervention is now closed.
Vitamin CDrug
Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses Note: this intervention is now closed.
No antiplateletOther
No antiplatelet agent or NSAID to be administered. Note: this intervention is now closed.
AspirinDrug
Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
P2Y12 inhibitorDrug
Site-selected P2Y12 inhibitor: * Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first. * Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day. * Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
No simvastatinOther
No simvastatin intended to be active against COVID-19 is to be administered Note: this intervention is now closed.
SimvastatinDrug
Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation Note: this intervention is now closed.
EritoranDrug
Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital Note: this intervention is now closed.
ApremilastDrug
Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
Clinician-preferred mechanical ventilation strategyProcedure
Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
Protocolised mechanical ventilation strategyProcedure
Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
No renin-angiotensin system inhibitorOther
No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10. Note: this intervention is now closed.
Angiotensin converting enzyme inhibitorDrug
Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
Angiotensin Receptor BlockersDrug
Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
ARB + DMX-200Drug
Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first. ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily. Note: this intervention is now closed.
No cysteamineOther
No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first. Note: this intervention is now closed.
CysteamineDrug
Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first. Note: this intervention is now closed.
Fixed-duration dexamethasoneDrug
6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
Baloxavir MarboxilDrug
Baloxavir marboxil administered on days 1 and 4 post-randomisation.
Five-days oseltamivir + baloxavir marboxilDrug
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
Ten-days oseltamivir + baloxavir marboxilDrug
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
No endothelial modulatorOther
No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
ImatinibDrug
Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
No Immune Modulator for InfluenzaOther
No immune modulating agent intended to be active against influenza is to be administered.
TocilizumabDrug
Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.
BaricitinibDrug
Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).
No antiviral agent for COVID-19Other
No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
Nirmatrelvir/ritonavirDrug
Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.
RemdesivirDrug
Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Nirmatrelvir/ritonavir + remdesivirDrug
Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Amoxicillin-clavulanate + Ceftazidime + MacrolideDrug
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Meropenem + MacrolideDrug
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival and Recovery Trajectory up to day 90Time frame: Day 90
Locations
408 sites in 29 countries. Site status is shown where the registry gives one.
University of Florida
Jacksonville, Florida · Recruiting
Augusta University
Augusta, Georgia · Not yet recruiting
University of Illinois Health
Chicago, Illinois · Recruiting
Tulane Medical Center
New Orleans, Louisiana · Not yet recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Wake Forest Baptist Health
Winston-Salem, North Carolina · Not yet recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
University of Pittsburgh Medical Centre
Pittsburgh, Pennsylvania · Recruiting
Brown University - Rhode Island Hospital
Providence, Rhode Island · Not yet recruiting
Canberra Hospital
Canberra, Australian Capital Territory, Australia · Recruiting
Bankstown-Lidcombe Hospital
Bankstown, New South Wales, Australia · Recruiting
Blacktown Hospital
Blacktown, New South Wales, Australia · Recruiting
Campbelltown Hospital
Campbelltown, New South Wales, Australia · Recruiting
Sutherland Hospital
Caringbah, New South Wales, Australia · Recruiting
Concord Hospital
Concord, New South Wales, Australia · Recruiting
Dubbo Base Hospital
Dubbo, New South Wales, Australia · Recruiting
Northern Beaches Hospital
Frenchs Forest, New South Wales, Australia · Recruiting
Nepean Hospital
Kingswood, New South Wales, Australia · Recruiting
St. George Hospital
Kogarah, New South Wales, Australia · Recruiting
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
John Hunter Hospital
Newcastle, New South Wales, Australia · Recruiting
Orange Health Service
Orange, New South Wales, Australia · Not yet recruiting
St Vincent's Hospital Sydney
Sydney, New South Wales, Australia · Recruiting
Prince of Wales Hospital
Sydney, New South Wales, Australia · Recruiting
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia · Not yet recruiting
Royal North Shore Hospital
Sydney, New South Wales, Australia · Recruiting
Wollongong Hospital
Sydney, New South Wales, Australia · Recruiting
Wagga Wagga Base Hospital
Wagga Wagga, New South Wales, Australia · Not yet recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Royal Darwin Hospital,
Darwin, Northern Territory, Australia · Not yet recruiting
Sunshine Coast University Hospital
Birtinya, Queensland, Australia · Not yet recruiting
The Prince Charles Hospital
Brisbane, Queensland, Australia · Recruiting
Mater Hospital Brisbane
Brisbane, Queensland, Australia · Recruiting
Princess Alexandra Hospital
Brisbane, Queensland, Australia · Recruiting
Caboolture Hospital
Caboolture, Queensland, Australia · Recruiting
Queen Elizabeth II Jubilee Hospital
Coopers Plains, Queensland, Australia · Recruiting
Logan Hospital
Logan City, Queensland, Australia · Not yet recruiting
Redcliffe Hospital
Redcliffe, Queensland, Australia · Not yet recruiting
Showing 40 of 408 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.